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Abstract A novel method allowing the conjugation of a fatty 
acid to a peptide or protein in aqueous buffer is described in this 
paper. L-Cysteinyl 2-pyridyl disulfide (CPD) (III), which was 
obtained by reacting L-cysteine (I) with 2,2-dithiopyridine (II), 
was reacted with the N-hydroxysuccinimide ester of palmitic acid 
(IV) to yield a water-soluble derivative of palmitic acid, termed 
Pal-CPD (V). Pal-CPD (V) could be reacted with a sulfhydryl-
containing peptide or protein in aqeous buffer to yield the palmitic 
acid-derivatized conjugate (VI). The palmitic acid-derivatized 
Bowman-Dirk protease inhibitor (BRI), synthesized using this 
conjugation method, was demonstrated to have 140-fold higher 
uptake into Caco-2 cell monolayers compared to native-BBI. The 
biological activity of the conjugate, as assessed using an in vitro 
transformation assay, was retained. 
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1. Introduction 
The effective delivery of therapeutic peptides and proteins to 
their site of action in vivo is an area of great importance in 
pharmaceutics and biotechnology. Peptides and proteins, as a 
class of macromolecules, are generally poorly transported 
across biological membranes. Hydrophilicity, the lack of 
stability due to enzymatic or chemical degradation. and the lack 
of transport carriers capable of shuttling proteins across cell 
membranes, all playa part in precluding proteins from uptake 
into and transport across biological barriers such as the blood 
brain barrier and the gastrointestinal mucosa [I]. 
One attractive approach for improving the transport proper-
ties of peptides and proteins is to conjugate with membrane-
binding carrier ligands. Hydrophobic carrier ligands. such as 
fatty acids, represent potentially one of the most useful types 
of carriers. and evidence suggests that fatty acid-conjugated 
peptides and proteins may be able to cross cell membranes. 
including the blood brain barrier [2]. Furthermore. several fatty 
acid-peptide conjugates, due to their amphipathic character. 
have been shown to possess important biological properties 
such as the immunostimulating activity [3,4]. 
However. the conjugation of fatty acids to peptides and pro-
teins is a challenging task with unique problems. The major 
difficulties in conjugating fatty acids to pep tides or proteins are 
the lack of solubility of both the fatty acid and the peptide or 
*Correspondmg author. Fax: (213) 342 1390. 
E-mail: welshen@hsc.usc.edu 
protein in the same solvent (organic or aqueous). and the loss 
of biological activity of peptides or proteins after fatty acid 
acylation [5.6]. In this paper. we present novel conjugation 
method which uses a water-soluble derivative of palmitic acid 
and allows an efficient and selective conjugation of a protein 
to a fatty acid. via a reversible disulfide linkage. Using this 
acylation method, we conjugated palmitic acid to Bowman-
Birk protease inhibitor (BBI). an 8 kDa soybean polypeptide 
with potential cancer chemopreventive uses in human [7]. 
2. Experimental 
2 1. SyntheSIS of L-cpteinyl 2-pyridyl dIsulfide (CPD) (II/) I 
L-Cysteine (3.0 g) (I) and 2.2-dithlOpyridine (II) (7.5 g) were mixed' 
in ethanoL and the reactIOn was allowed to proceed at 25°C for 18 h. 
The solution was centrifuged in order to remove any preCipitate, and 
CPD (III) m the supernatant was crystallized by the additIOn of cold 
benzene. The final product after recrystallized in benzene was a white 
solid With a m.p. (With decomposition) of 158°C. The molar yield of 
the product using thiS procedure was approximately 60%. 
2.2. Synthesis of Pal-CPD (V) 
Triethylamine (100 ,ul) was added to a solution ofCPD (100 mg) (III) 
in 5 ml of dimethylformamlde (DMF) and the resultant suspensIOn was 
reacted With the N-hydroxysuccmlmlde ester of palmitic aCid (IV) 
(250 mg) in DMF (5 ml) at 25°C for 24 h. dunng which time the 
suspenslOn<lurned clear. This solutIOn was diluted With 40 ml of ice-cold 
water and the preCipitate. which contained Pal-CPD (V) and palmitic 
acid. was Isolated py centnfugatlOn. Pal-CPD (V) was separated from 
palmitic by suspension of the preCIpitate m water at pH 7.0, which 
dissolved Pal- CPD (V). but not palmitic acid. Pal-CPD (V) was pun-
fied by repeatmg preclpltatlOn at pH 3 and was analyzed by using NMR 
and TLC techniques. 
23 SyntheSIS of SPDP-modified BBI (BBI-PDP) 
BBI (20 mg) was reacted with 3-(2-pyridyldlthio) propiomc acid 
N-hydroxysuccimmlde ester (SPDP. 5 mg in 100,u1 of DMF) mImI 
of sodIUm bicarbonate buffer (0.3 M. pH 8.0) for 2 h at 25°C. After 
purificatlOn of BBI-PDP usmg Sephadex G-50 gel-filtration chroma-
tography. the extent of modification of BBI was estimated by measur-
ing the release of the thlOpyridme after the reductlOn of BBI-PDP with 
dithlOthreltol (DTT). Usmg this procedure, approximately 4 amino 
groups per BBI molecule were modified with SPDP. 
24. SyntheSIS vj BBlssPul ( VI) 
BBI-PDP (20 mg) dissolved mImi of PBS was adjusted to pH 5.0. 
reduced With DTT (25 mM) for 30 mm. and subsequently eluted from 
a Sephadex G-50 column. The sulfhydryl-containmg BBI fractions. 
which eluted at column vOId volume. were identified using Elman's 
reagent, and then reacted With a 3-fold excess (per sulfhydryl group on 
BBl) ofPal-CPD (V) in pH 70 phosphate buffered saline (PBS) for 16 h 
at 4°C. The reactlOn mixture was then aCidified to pH 3.0 usmg I N 
HCI and the precipitate. which con tamed all of BBIssPal (VI) and the 
excess reagent of (V). was Isolated by centnfugation. The precipitate 
was dissolved m DMF and eluted from a Sephadex LH-20 column 
usmg DMF. BBIssPal (VI). was Isolated from fractions eluted at 
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column void volume. The yield of the conjugate using this procedure 
was approximately 80% (by weIght of BBI). The conjugation and the 
ratio of fatty acid to BBI in the conjugate was confirmed by usmg 
eH]palmitic acid as a tracer m a separate. but identIcal. set of experi-
ments as described above. 
2.5 The uptake of t 25IjBBIssPa/ by Caco-2 ceUs 
RadioiodinatlOn of BBI and BBIssPal was carned out using the 
chloramine-T method [8]. Confluent, 14-day-old Caco-2 cell monolay-
ers were washed once and then incubated with serum-free Dulbecco 
medium at 37°C for 30 min. Subsequently. the incubation media was 
replaced with media containing [125I]BBI (lO,ug/ml), either as native-
BBI or as BBIssPal. and the mono layers were incubated for a further 
60 mm at 37°C. The monolayers were then washed three times with 
ice-cold pH 7.0 PBS. and then exposed to trypsm for 10 min at 37°C. 
The detached cells were transferred to tubes. Isolated by centrifugation, 
washed three times using ice-cold PBS, assayed for accumulated 
radIOactIvity using a gamma counter. and finally assayed for cell pro-
tein using the method of Lowry [9] BBIssPal reduction was carried out 
at 37°C for 30 min using DTT (50 mM). 
::.6. In vitro transformation assay 
The transformation assays were carried out using C3HIOTl/2 (clone 
8) cells according to the procedure described by Rezmkoff et al. [10]. 
Briefly. C3HIOTl/2 cells were seeded mto 60 mm dIshes (20 dishes per 
each group of treatment) at a density of 1.000 cells/dish. After 24 h. cells 
were treated with 3-methylcholanthrene (MCA) at a final concentration 
of l,ug/ml in the medium. The cells were allowed to grow m the presence 
of MCA for 24 h and the medium in each dish was replaced with fresh 
MCA-free medium, and subsequently the medium was replaced twice 
a week for two weeks and then once a week for four more weeks. For 
the measurement of anti-transformation activity, BBI or BBIssPal 
(I,ug/ml) was included m the medium in some dishes after the MCA-
treatment for the first 3 weeks only. Six weeks after the MCA-treat-
ment, the cells were washed. fixed and stained with Giemsa stain. The 
transformed foci (> 3 mm in dIameter) in the dishes were examined 
under a microscope to score as type L II, and III [10]. Only type II and 
III foci were used to evaluate the antI-transformation actIVIty of BBI 
and BBIssPal. 
3. Results and discussion 
It has been demonstrated that the transport properties of 
pep tides and proteins into and across cell barriers in vitro and 
in vivo can be drastically improved by conjugation with mem-
brane-binding ligands. For instance, polylysine [I I]. transferrin 
[12]. antibodies [13], folic acid [14] and spermine [IS] have been 
used as carrier ligands. capable of transporting proteins into 
and even across cell barriers in vitro. Hydrophobic ligands, 
such as fatty acids, have also been used as transport ligands in 
vitro [6] and in vivo [2.16], and conceivably. because of high 
membrane affinity and low toxicity. may represent the most 
useful carrier ligands for conjugation to pep tides and proteins. 
The conjugation of fatty acids to peptides and proteins is. 
however, a challenging task, made particularly difficult by the 
Table 1 




Uptake (ng BBI/mg of cell protein)b 
Serum-freec 1 % FBSc 10% FBS' 
3.9 ± 0.19 
540.0 ± 24.13 
2.2 ± 0.17 
78.5 ± 3.41 
1.3 ± 0.02 
129±0.02 
aThe cell monolayers were mcubated WIth 125I-labeled conjugates at 
10 ,ug/ml for 60 min at 37°C. 
bThe results presented are the average of three monolayers ± S.E.M 
C The uptake experiments were carned out m Dulbecco medium. in the 
presence and absence of added FBS. 
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lack of solubility of peptides and proteins in organic solvents 
and by the possible loss of biological activity of peptides and 
proteins after fatty acid acylation [S,6]. Fatty acids have been 
conjugated to peptides and proteins in organic solutions either 
directly [6.16.1 7] or using reverse phase micelles [2,18]. and in 
aqueous solutions using micelluar suspensions [19,20] contain-
ing reactive fatty acid derivatives. 
In contrast to other fatty acid conjugation methods. the pro-
cedure described in this paper allows the selective attachment 
of a hydrophobic ligand to pep tides and proteins in aqueous 
buffer. avoiding the need to expose peptides and proteins to 
organic liquids during the conjugation process. Also, the conju-
gation method presented here is based on the covalent attach-
ment of a fatty acid to a protein via a reversible disulfide 
linkage. We believe the use of the disulfide linkage offers two 
major advantages. Firstly, the reversible, biodegradable nature 
of the bond should allow for the regeneration of the active 
peptides and proteins after cellular reduction of the disulfide 
linkage in the conjugate [21]. Secondly. recent data suggest that 
the transcytosls of a protein-macromolecule conjugate across 
cell barriers can be achieved only if a reducible, reversible 
linkage is used in the conjugation of the macromolecule to the 
protein [22]. 
As an example of this acylation method, we conjugated 
palmitic acid to Bowman-Birk protease inhibitor (BBI). BBI is 
an 8kDa soybean polypeptide with both trypsin and chymot-
rypsin inhibitory activities [7]. It has been shown that BBI is 
capable of preventing transformation in vitro [23] and carcino-
genesis in vivo [24]. and it is currently being investigated as a 
potential cancer chemopreventive agent for use in humans. It 
has been suggested that BBI acts intracellularly to prevent the 
transformation [2S-27]. Conceivably, improving the cell uptake 
properties of BBI may enhance the cancer chemopreventive 
potential of this polypeptide. 
The synthetic route for BBIssPal is shown in Fig. 1. The cell 
uptake of C25I]BBI, either as the native polypeptide or as 
BBlssPal, was studied in Caco-2 cell mono layers in the presence 
and absence of fetal bovine serum (FBS); the results are pre-
sented III Table I. When the uptake studIes were carried out in 
serum-free medium, BBIssPal demonstrated high affinity to-
wards cell mono layers in vitro and was transported into cells 
by a 140-fold higher level compared to native BBI. The addition 
of serum to the medium greatly reduced the uptake of BBIssPal 
into cells in a concentration dependent manner. reducing the 
uptake by 8S% and 98% III the presence of I % and 10% FBS, 
respectively. These results can be explained by the affinity of 
BBIssPal towards not just the cell membrane. but also other 
components in serum. In particular, binding to fatty acid bind-
Table 2 
The uptake of C25I]BBI. either as the natIve polypeptIde or as BBlssPal, 
by Caco-2 cells before and after reductIOn WIth DTP 
BBI 
BBlssPal 
Uptake (ng BBI/ mg of cell protem)b 
UntreatedC 
4.8 ± 0.00 
381.7 ± 0.03 
DTT-treatedC 
5.2 ± 0.00 
46.5 ± 0.00 
"The cell monolayers were mcubated with 125I_labeled conjugates at 
10,ug/ml in serum-free Dulbecco medium for 60 min at 37°C 
b The results presented are the average of three monolayers ± S.E.M. 
C [
125I]BBL eIther as the natIve protem or as BBIssPal. was incubated 
at 37°C for 30 min m the presence and absence of DTT (50 mM). 
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A) 
(I) (II) (III) 
B) (Ill) + ~~oJ-(CH')"CH' 
o 
(IV) (V) 
C) (V) + (protein} SH -----.. 
TOOH R 
(protein}- SS-CH2-CH-NH- C-(CH:J14CH3 
(VI) 
Fig.!. Protem-palmitic aCid conjugation usmg Pal-CPO (V). Pal-CPO (V) IS synthesized m two steps: A and B. A protem contaming a sulfbydryl 
group can then be reacted with Pal-CPO (V) m an aqueous buffer to yield the fatty acid-derivatlzed conjugate 
ing proteins may account for the reduced uptake of BBlssPal 
into cells in the presence of serum. To demonstrate that the 
higher uptake of BBIssPal was mediated by the palmitic acid 
moiety in the conjugate, BBlssPal was reduced with DTT and 
the cell uptake in serum-free medium are shown in Table 2. The 
DTT treatment causes the reduction of disulfide linkages in 
BBIssPal and the detachment of the palmitic acid moiety from 
the conjugate. As presented in Table 2, the reduction with OTT 
resulted in a drastic decrease in the uptake of BBIssPal into 
cells. On the other hand, the uptake of unmodified BBI into 
cells was not influenced by the DTT treatment (Table 2). We 
also investigated the biological activity of BBIssPal using an III 
vitro transformation assay procedure [10], which was have used 
for the studies of other BBl conjugates [14,20]. The results 
indicated that BBIssPal is effective in preventing chemical-in-
duced transformations in C3HlOTI/2 cells in vitro (Table 3). 
Table 3 
Similar studies have also been observed in radiation-induced 
transformation assay (data not shown). Hence, in addition to 
having improved cell uptake properties, BBIssPal also retains 
the anticarcinogenic activity of the native BBI. However, since 
a dose-response relationship for the effectiveness of BBI III 
suppressing transformation III cell culture systems does not 
vary with concentrations of BBI ranging over orders of magni-
tude [28], no attempt was made in this report to correlate the 
increase of uptake with the anti-transformation activity of 
BBlssPal at extremely low concentratIOns C3H1OTlI2 cells. 
In summary, we conclude that: (a) the conjugation procedure 
described in this paper is an efficient and selective method of 
fatty acid conjugatIOn to pep tides or proteins; (b) fatty acid-
conjugated proteins have high affinity towards cell monolayers 
in vitro, but can also bind other serum proteins factors; (c) the 
uptake of fatty acid conjugated polypeptides is mediated by the 
Effect of BBI and BBlssPal" on chemlcal-mduced transformation in C3H IOTl/2 cells 
Treatment group 
I Controls-untreatedb 
2. Negative controls-acetone-treatedb 
3. Positive controls-MCA-treatedb 
4. Test-MCA-treated + BBIb 
5. Test-MCA-treated + BBIssPalb 
Platmg effiClency (%) 
23 ± 1.5 
22 ± 2.0 
21 ± 3.0 
24 ± 2.0 
23 ± 3.0 
No. of dishes With transformed 













., BBL either as the free protein or m conjugated form to palmitic aCid, was added to the cultures at 1.0 ,ug/ml for the first three weeks of the 
transformatIOn assay penod starting Immediately after the MCA treatment. 
b MCA-treated cells were exposed to 3-methylcholantherene, dissolved in 25 ,ul of acetone, at a concentratIOn of 1 ,ug/ml for 24 h Acetone-treated 
celb were exposed to 25,u1 of acetone for 24 h only. The test groups were exposed to MCA for 24 h and then to the conjugates for the first three 
weeks of the assay. Untreated cells were exposed to neither MCA nor acetone. 
'Statistical analYSIS tx square): Group 4 vs. 3, P < 0.05; Group 5 vs. 3,0.05 < P < 0.1. 
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lipophilicity of the fatty acid moiety in the conjugate; and (d) 
the biological activity of the peptide or protein may be retained 
in the fatty acid conjugate. 
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